Sales momentum accelerated in Q1 21 driven by a strong show in Personal Health and a strengthening performance in D&T. Order intake growth in D&T was in double-digit territory, which is also encouraging. Margin advancement – driven by sales growth and productivity measures – was better than expectations. Given the robust momentum, FY21 sales target has been upgraded. However, the strong results were overshadowed by some quality issues (booked a €250m provision) with certain sleep and respiratory
Companies: Koninklijke Philips N.V.
FY20 ended on a promising note with strong organic sales and order growth as well as margin expansion – mainly driven by the third consecutive quarter of double-digit growth in Connected Care. Notably, Personal Health sustained its mid-single-digit growth, while D&T returned to growth in Q4 20. Given the pandemic is still continuing, management expects a strong H1 21 on the back of sustained demand for acute care and precision diagnosis equipments. Easy comps should also lend support.
Sales growth momentum is likely to accelerate in the mid-term on the back of the growth in core businesses and increasing demand for integrated AI solutions. Connected Care should benefit from structural tailwinds and growth in Personal Health should be innovation-driven. D&T should profit from its solution-centric approach. Top this up with the operating margin advancement target of 60-80bp, including the targeted productivity savings of €2bn, adjusted EPS is likely to grow by c.10% p.a. until
Philips returned to growth in Q3, driven by robust demand for patient monitors and ventilators and a solid rebound in Personal Health. D&T also saw an improvement, though it is still in the red. Profitability improved considerably, benefiting from operational leverage and productivity measures. Management anticipates low single-digit sales growth for FY21 and an acceleration in the mid-term (+5-6%) with all segments growing within this range. The EBITA margin is likely to improve 60-80bp annuall
The Q2 slump was less severe than feared. Connected Care saw a double-digit increase, led by ventilators, though momentum was offset by reduced consumer demand for Personal Health products. D&T was impacted by the postponement of installations and elective procedures. In H2, the robust order book should ensure steady growth in Connected Care and a rebound in elective procedures could bolster growth in D&T. Improving consumer demand bodes well for Personal Health. Ergo, sales should be back in th
COVID-19 lowered sales by 5ppt in Q1 as increased demand for professional healthcare products was more than offset by the decline in demand for personal health products, particularly in China. Lower sales and an unfavourable product mix suppressed profitability. Considering that the virus has spread to the western world, Q2 is expected to be worse. Nonetheless, management anticipates a recovery in H2 and thus guided for modest sales growth and margin improvement for FY20. Robust order intake gro
Impacted by slowdown across all three segments, Philips’ organic growth slipped to +3.3% in Q4 – D&T was held back by imaging and CC was affected by SRC. PH suffered due to negative growth in domestic appliances. Nonetheless, the FY19 revenue and profitability targets were achieved. Considering that domestic appliances does not fit into Philips health-tech strategy anymore, management is exploring strategic options – the proceeds could be channelled towards acquisitions in the healthcare space.
Led by double-digit growth in China and the robust performance in D&T and PH, sales accelerated slightly in Q3 19. However, order intake was flat due to softness in North America. Also, margins were held back by the adverse effect of tariffs, particularly in CC. As the mitigating actions (to counter tariffs) begin to bear fruit, we anticipate a margin advancement in Q4. Also, the c.100bp margin improvement target for FY20 appears within reach, given the positive growth trajectory in D&T and PH.
After a soft start in Q1, organic sales accelerated significantly in Q2 as mature markets and the Connected Care segment returned to growth. The D&T segment also reported a step-up in sales, while the Personal Health division continued with its MSD growth. With comparable order intake growth also witnessing acceleration, sales in H2 are likely to be stronger than in H1. Profitability should also improve further, led by operational leverage and efficiency initiatives.
Q1 was soft with negative lfl growth in Connected Care, decelerated sales growth momentum in D&T and a dismal showing in mature markets. But, Personal Health regained momentum and emerging markets posted double-digit comparable sales and order intake growth, which was a positive. Given the robust order book, particularly in Europe and North America, momentum should accelerate in the coming quarters and thus the FY19 financial targets should be met.
Royal Philips ended the year on a high with revenue as well as profits exceeding expectations – sustained growth in D&T overshadowed the slowdown in PH and CC&HI. Shareholders were rewarded handsomely with a 6% increase in dividends for FY18 and a new two-year €1.5bn share buy-back programme. Given the robust order intake growth (for D&T and CC&HI) and the continuous focus on new product launches (particularly PH), Philips remains on track to meet its financial targets for FY19.
At its Capital Markets Day, Royal Philips reiterated its financial targets of 4-6% comparable sales growth pa during FY18-20 and EBITA margin expansion of 100bp per year until FY20. Segment-wise, the revenue guidance for the Diagnostics & Treatment/D&T segment (c.39% of sales) has been upgraded to 5-7% pa (vs. previous guidance of 3-5%) while the EBITA margin target of 14-16% has been maintained (to allow for extra room for investments). The revenue and profitability guidance for the Personal He
Q3 was a weak quarter. While the sales momentum was held back by a dismal show in the CC&HI segment and a slower than expected recovery in the Personal Health division, profitability was impacted by adverse currency movements and increased investments in sales and marketing. However, robust comparable sales as well as order intake growth in D&T should enable Philips to meets it financial targets for FY18. Nonetheless, the US-China trade war and Brexit remain the key headwinds for FY19.
Q2 was a mixed quarter wherein comparable sales were a tad below estimates while profitability met expectations. A slowdown in the PH segment, particularly in China, was the main reason behind the sales miss. However, we view this as a one-off and, given the seasonality of the business, we expect an acceleration in H2 18. Also, given a strong order book in D&T, we believe that the company would be able to meet its sales and profitability targets for FY18.
With comparable sales growth of 5.1%, order intake growth of 10% and margin expansion of 130bp, Royal Philips started FY18 on a promising note. Robust growth in the D&T segment led to the outperformance, despite deceleration in the PH and CC&HI segments. Given a strong order book, we expect the comparable sales growth to reach the middle of the guidance range of 4-6% in FY18. The target price resets higher by c.4%.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Koninklijke Philips N.V..
We currently have 0 research reports from 0
OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri
Companies: OptiBiotix Health PLC
Venture Life has announced it has entered into a Revolving Credit Facility (RCF) with Santander UK and Silicon Valley Bank. The funds, of up to £50m, provide leverage to the company's existing cash resources, and will support management's M&A ambitions, following the recent acquisition of BBI Healthcare for c£36m. We remain encouraged by Venture Life actively progressing its overall M&A strategy, which we expect to scale the company and provide operational leverage opportunities to maximise the
Companies: Venture Life Group Plc
CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported
Companies: CareTech Holdings PLC
As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne
Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK
In this week’s edition of Liberum's Podcast - Best Idea of the Week, Ed Blair talks to Graham Doyle of Liberum's Healthcare team to discuss his recent sector note. Graham explains why UK Healthcare is likely to face macro headwinds over the next six months, why Medica and PureTech are the Top Picks during this period and why there may be an opportunity from a lagging reopening trade in healthcare.
Companies: Medica Group Plc (MGP:LON)PureTech Health PLC (PRTC:LON)
VLG has agreed a new £30m RCF (with a further £20m available subject to certain conditions). This provides significant additional low-cost funding to continue its growth strategy, including accretive acquisitions. With an exciting pipeline of opportunities, and a strong track record of delivery (including realisation of synergies), this news should be well received. In the first full year of earnings and synergy from its most recent BBIH acquisition, the EV/EBITDA multiple is currently just 10x
Calnex Solutions has announced record results for FY21 following customer orders up across all product types and within all regions, with FY21 revenue up 31% to £18.0m and adjusted PBT up 43% to £5.1m. Calnex has firmly established a trusted reputation worldwide, launching multiple first to market telecoms and network testing solutions. Calnex continues to accelerate its investment in R&D and expand its product roadmap, adding increased engineering, sales and customer support capacity in order t
Companies: Calnex Solutions Plc
There has been a safety halt to the lead human retinal progenitor cell (hRPC) project. The issue was an eye infection in one patient following a successful surgical implantation of the hRPC. The cause is under investigation. If, as we assume, the trial restarts in the next few months, data should be available by Q421, a delay of perhaps three months. This is not significant within the overall developmental pathway and good data are needed to secure any future partnership from mid-2022. The valua
Companies: ReNeuron Group plc
SUN’s AGM statement paints a picture of a business recovering well after the challenges posed by the pandemic. It has successfully won new accounts in the UK and US on the back of its strong environmental and health economic credentials. These look to be increasingly resonating and are laying the foundations for a powerful growth story as elective surgery volumes recover. This should be sustained into the medium term as healthcare systems around the world look to reduce waiting times, costs and
Companies: Surgical Innovations Group plc
SDI Group has published a second positive trading update ahead of July’s FY21E results announcement. Management’s guidance for revenue and adjusted PBT is approximately £35.3m and £7.4m respectively, ahead of our previous FY21E estimates (and previous guidance) of £34.0m and £6.7m. We upgrade our FY21E forecasts accordingly, with a 10% uplift to our fully adjusted PBT forecast. Current base guidance for FY22E remains unchanged with revenue of £42m and adjusted PBT of £8.7m. Consequently, we are
Companies: SDI Group plc
In an encouraging sign of building US momentum, Yourgene has announced it has signed a multi-year licence and supply agreement with a major US precision medicine company to enable it to offer a new reproductive health screening service from its own laboratories. The agreement encompasses a non-exclusive licence to Yourgene’s proprietary bioinformatics Flex analysis software and a supply agreement for sample preparation reagents and instrumentation. Notably, this includes the Ranger sample enrich
Companies: Yourgene Health Plc
Belluscura is a medical device company focused on developing lightweight and portable oxygen enrichment technology. The group completed its IPO in June, raising £17.5m at a price of 45p. Following IPO, the group has appointed a VP of Operations and this morning has confirmed its first US distribution deal. On 15th June, the group announced the appointment of Keith Cook as Vice President of Operations, based in Plano, Texas. Keith was previously Director of Operations at Inogen, the market leader
Companies: Belluscura PLC
Calnex Solutions is a leading provider of test and measurement hardware and software solutions that enable performance validation and standards conformance of critical infrastructure associated with telecoms and high-speed data networks. 5G network evolution is a significant, long-term driver of growth for the business along with the continued expansion of hyperscale datacentre enterprises and their increasing participation in telecoms infrastructure markets. Calnex has established a trusted rep
Half-year results to December 2020 reflect a period in which genedrive has made notable strides, but also reflect frustrating delays in commercialising its products, largely due to factors outside of its control. genedrive generated revenues of £0.4m in the half-year (2019: £0.6m, -43%), with an adjusted net loss of £2.9m (2019: -£2.8m, -3%) with cash of £3.8m at the end of the period. genedrive remains hopeful for FDA emergency use authorisation (EUA) for Genedrive 96® SARS-CoV-2 and remains in
Companies: Genedrive Plc
The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa
Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN